Completed PHASE4 INTERVENTIONAL 3-arm NCT04427956

Corneal Crosslinking Treatment Study

Prospective Randomised Corneal Crosslinking Study

Sponsor: Region Skane

Interventions Corneal crosslinking: CXL (UVA 9mW/cm2) Hypotonic riboflavin Iontophoresis Isotonic riboflavin

Updated 11 times since 2020 Last updated: Nov 19, 2024 Started: May 23, 2017 Primary completion: Nov 19, 2024 Completion: Nov 19, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Progressive Keratoconus, this trial is completed. The trial is conducted by Region Skane and has accumulated 11 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Dec 2024 — Present [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE4
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE4
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE4
Mar 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting

▶ Show 6 earlier versions

Jun 2023 — Mar 2024 [monthly]

Recruiting PHASE4
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE4
Nov 2022 — Apr 2023 [monthly]

Recruiting PHASE4
Nov 2021 — Nov 2022 [monthly]

Recruiting PHASE4
Jan 2021 — Nov 2021 [monthly]

Recruiting PHASE4
Jul 2020 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Region Skane

Data source: Region Skane

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lund, Sweden